PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer

Qing Li,Zhi-Wei Zhou,Jia Lu,Hao Luo,Shu-Nan Wang,Yu Peng,Meng-Sheng Deng,Guan-Bin Song,Jian-Min Wang,Xi Wei,Dong Wang,Kenneth D. Westover,Cheng-Xiong Xu

DOI: https://doi.org/10.1016/j.ymthe.2021.09.013

IF: 12.91

2022-02-01

Molecular Therapy

Abstract:Cancer cells evade immune detection via programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) interactions which inactivate T cells. PD-1/PD-L1 blockade has become an important therapy in the anti-cancer armamentarium. However, some patients do not benefit from PD-1/PD-L1 blockade despite expressing PD-L1. Here, we screened 101 gastric cancer (GC) patients at diagnosis and 141 healthy controls and reported one such segment of GC patients with rs17718883 polymorphism in PD-L1, resulting in a nonsense P146R mutation. We detected rs17718883 in 44% of healthy controls, and rs17718883 was associated with a low susceptibility to GC and better prognosis in GC patients. Structural analysis suggests the mutation weakens the PD-1:PD-L1 interaction. This was supported by co-culture experiments of T cells with GC cells showing that the P146R substitution results in INF-γ secretion by T cells and enables T cells to suppress GC cell growth. Similar results with animal gastric tumor models were obtained in vivo. PD-1 monoclonal antibody treatment did not enhance the inhibitory effect of T cells on GC expressing PD-L1P146R in vitro or in vivo. This study suggests that rs17718883 is common and may be used as a biomarker for exclusion from PD-1/PD-L1 blockade therapy.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology